Literature DB >> 30667469

Estimates of the Number of Brand-name Drugs Affected by the Medicaid Rebate Cap in 2017.

Sean Dickson1.   

Abstract

Mesh：

Year:  2019        PMID： 30667469      PMCID： PMC6439693          DOI： 10.1001/jamainternmed.2018.6559

Source DB:  PubMed          Journal:  JAMA Intern Med        ISSN： 2168-6106            Impact factor:   21.873


× No keyword cloud information.
  1 in total

1.  Differences Between Managed Care and Fee-for-Service Medicaid in the Use of Generics for High-Rebate Drugs: The Cases of Insulin Glargine and Glatiramer.

Authors:  Inmaculada Hernandez; Walid F Gellad
Journal:  J Manag Care Spec Pharm       Date:  2020-02
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.